Quantum Genomics SA
Quantum Genomics Société Anonyme is in the process of liquidation of its remaining assets. Previously, the company was engaged in the development of drugs to treat cardiovascular diseases. Quantum Genomics Société Anonyme was incorporated in 2005 and is headquartered in Paris, France.
Quantum Genomics SA (ALQGC) - Net Assets
Latest net assets as of December 2024: €-2.46 Million EUR
Based on the latest financial reports, Quantum Genomics SA (ALQGC) has net assets worth €-2.46 Million EUR as of December 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€354.65K) and total liabilities (€2.81 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-2.46 Million |
| % of Total Assets | -692.5% |
| Annual Growth Rate | N/A |
| 5-Year Change | -109.96% |
| 10-Year Change | -130.62% |
| Growth Volatility | 304.42 |
Quantum Genomics SA - Net Assets Trend (2009–2024)
This chart illustrates how Quantum Genomics SA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Quantum Genomics SA (2009–2024)
The table below shows the annual net assets of Quantum Genomics SA from 2009 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €-2.46 Million | -662.43% |
| 2023-12-31 | €436.66K | -87.90% |
| 2022-12-31 | €3.61 Million | -62.68% |
| 2021-12-31 | €9.67 Million | -60.79% |
| 2020-12-31 | €24.65 Million | +162.11% |
| 2019-12-31 | €9.41 Million | -20.74% |
| 2018-12-31 | €11.87 Million | +33.77% |
| 2017-12-31 | €8.87 Million | -24.77% |
| 2016-12-31 | €11.79 Million | +47.00% |
| 2015-12-31 | €8.02 Million | +6280.61% |
| 2014-12-31 | €-129.79K | +92.03% |
| 2013-12-31 | €-1.63 Million | -77.37% |
| 2012-12-31 | €-918.08K | -378.78% |
| 2011-12-31 | €329.32K | +701.69% |
| 2010-12-31 | €41.08K | -86.80% |
| 2009-12-31 | €311.08K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Quantum Genomics SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 846491800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €2.79 Million | % |
| Other Components | €4.61 Million | % |
| Total Equity | €-2.46 Million | 100.00% |
Quantum Genomics SA Competitors by Market Cap
The table below lists competitors of Quantum Genomics SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Only World Group Holdings Bhd
KLSE:5260
|
$4.43 Million |
|
Patentus SA
WAR:PAT
|
$4.43 Million |
|
Vital Metals Ltd
AU:VML
|
$4.43 Million |
|
Ikapharmindo Putramas Tbk.
JK:IKPM
|
$4.43 Million |
|
Country Club Hospitality & Holidays Limited
NSE:CCHHL
|
$4.42 Million |
|
Anew Medical, Inc.
NASDAQ:WENA
|
$4.42 Million |
|
Prg Holdings Bhd
KLSE:7168
|
$4.42 Million |
|
Tincorp Metals Inc.
OTCQX:TINFF
|
$4.42 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Quantum Genomics SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 436,664 to -2,455,942, a change of -2,892,606 (-662.4%).
- Net loss of 8,892,603 reduced equity.
- Other factors increased equity by 5,999,997.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-8.89 Million | -362.09% |
| Other Changes | €6.00 Million | +244.31% |
| Total Change | €- | -662.43% |
Book Value vs Market Value Analysis
This analysis compares Quantum Genomics SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | €0.05 | €0.07 | x |
| 2010-12-31 | €-3.05 | €0.07 | x |
| 2011-12-31 | €-1.79 | €0.07 | x |
| 2012-12-31 | €-0.41 | €0.07 | x |
| 2013-12-31 | €-0.38 | €0.07 | x |
| 2014-12-31 | €-0.03 | €0.07 | x |
| 2015-12-31 | €1.16 | €0.07 | x |
| 2016-12-31 | €1.26 | €0.07 | x |
| 2017-12-31 | €0.81 | €0.07 | x |
| 2018-12-31 | €0.76 | €0.07 | x |
| 2019-12-31 | €0.52 | €0.07 | x |
| 2020-12-31 | €1.21 | €0.07 | x |
| 2021-12-31 | €0.36 | €0.07 | x |
| 2022-12-31 | €0.10 | €0.07 | x |
| 2023-12-31 | €0.01 | €0.07 | x |
| 2024-12-31 | €-0.04 | €0.07 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Quantum Genomics SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -88926030.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-909.87%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | -12495.17% | -7211.41% | 0.02x | 76.34x | €-1.39 Million |
| 2010 | 0.00% | -6935.56% | 0.02x | 0.00x | €-1.26 Million |
| 2011 | 0.00% | -4468.13% | 0.02x | 0.00x | €-816.81K |
| 2012 | 0.00% | -4392.68% | 0.02x | 0.00x | €-751.59K |
| 2013 | 0.00% | -8858.79% | 0.01x | 0.00x | €-1.38 Million |
| 2014 | 0.00% | -680.49% | 0.07x | 0.00x | €-2.19 Million |
| 2015 | -46.92% | -2611.57% | 0.01x | 1.31x | €-4.57 Million |
| 2016 | -49.80% | 0.00% | 0.00x | 1.38x | €-6.29 Million |
| 2017 | -105.75% | 0.00% | 0.00x | 1.57x | €-10.27 Million |
| 2018 | -101.03% | -325286.35% | 0.00x | 1.56x | €-13.18 Million |
| 2019 | -96.52% | -586.84% | 0.10x | 1.57x | €-10.02 Million |
| 2020 | -65.81% | -887.04% | 0.06x | 1.33x | €-18.69 Million |
| 2021 | -179.57% | -553.19% | 0.15x | 2.20x | €-18.33 Million |
| 2022 | -691.19% | -991.45% | 0.11x | 6.56x | €-25.30 Million |
| 2023 | -726.18% | -16018.12% | 0.01x | 8.58x | €-3.21 Million |
| 2024 | 0.00% | -88926030.00% | 0.00x | 0.00x | €-8.65 Million |
Industry Comparison
This section compares Quantum Genomics SA's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $11,397,324
- Average return on equity (ROE) among peers: -51.25%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Quantum Genomics SA (ALQGC) | €-2.46 Million | -12495.17% | N/A | $4.43 Million |
| Abionyx Pharma SA (ABNX) | $8.89 Million | -56.01% | 1.06x | $71.47 Million |
| Abivax SA (ABVX) | $56.72 Million | -25.23% | 0.07x | $3.88 Billion |
| Adocia (ADOC) | $-6.91 Million | 0.00% | 0.00x | $84.43 Million |
| Aelis Farma SA (AELIS) | $898.00K | 63.92% | 30.53x | $5.17 Million |
| Acticor Biotech SAS (ALACT) | $-4.04 Million | 0.00% | 0.00x | $2.13 Million |
| NicOx S.A. (ALCOX) | $21.41 Million | -97.51% | 1.47x | $28.49 Million |
| Advicenne (ALDVI) | $-1.67 Million | 0.00% | 0.00x | $15.34 Million |
| ALGAE (ALGAE) | $32.76 Million | -39.31% | 0.56x | $30.55 Million |
| Genoway (ALGEN) | $5.23 Million | 9.60% | 1.10x | $24.14K |
| Integragen (ALINT) | $691.87K | -367.93% | 7.36x | $431.37K |